Form 8-K - Current report:
SEC Accession No. 0001493152-24-038129
Filing Date
2024-09-25
Accepted
2024-09-25 16:36:17
Documents
22
Period of Report
2024-09-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 76205
2 ex10-1.htm EX-10.1 237909
3 ex10-2.htm EX-10.2 114950
4 ex10-3.htm EX-10.3 85908
5 ex10-4.htm EX-10.4 136049
6 ex10-5.htm EX-10.5 152754
7 ex10-6.htm EX-10.6 115506
8 ex10-7.htm EX-10.7 53060
9 ex10-8.htm EX-10.8 15504
  Complete submission text file 0001493152-24-038129.txt   1368960

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE erna-20240924.xsd EX-101.SCH 3015
11 XBRL LABEL FILE erna-20240924_lab.xml EX-101.LAB 34240
12 XBRL PRESENTATION FILE erna-20240924_pre.xml EX-101.PRE 24165
25 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 241325069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)